Girocitinib
Small molecule
Evidence outlook · regulatory review
Rheumatoid Arthritis: application under NMPA (CDE) review
China's CDE proposes priority review for girocitinib (TLL-018) in rheumatoid arthritis (2026-09-24). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Also in development:PsoriasisChronic Spontaneous Urticaria
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other TYK2/JAK1 drugs
brepocitinib, Soficitinib (ICP-332), BHV-8000, TDM-180935. Compare all 5 TYK2/JAK1 drugs
4 other tracked programmes target this mechanism.
This drug's own stage for Chronic Spontaneous Urticaria: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Girocitinib: this drug | Stage not on record | Small molecule | TYK2/JAK1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Omalizumab (Xolair) | Approved | Monoclonal antibody | IgE (immunoglobulin E), IgE | Partial signal | NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73) NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results). | |
| Remibrutinib | Approved | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 3 | Monoclonal antibody | KIT | Partial signal | NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). | |
| BHV-8000 | Phase 2/3(overall) | Small molecule | TYK2/JAK1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-3095 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TDM-180935 | Phase 2(overall) | Small molecule | TYK2/JAK1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Briquilimab | Phase 1/2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| SAR449028 | —(overall) | Undisclosed | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3095 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent